RxDoctor Payments DataLook up a doctor →

Eric Awad, MD

Neurology · Atlanta, GANPI 1578557500

Payments from drug & device makers

$484,725in general payments, 2019–2025

Across 1,594 payments — averaging $304.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eisai Inc.$216K
  • Sage Therapeutics, LLC$146K
  • Lilly USA, LLC$66K
  • Idorsia Pharmaceuticals US Inc$23K
  • AbbVie$5K
  • Genentech USA, Inc.$5K
  • plus $23K from 54 others

What the payments were for

  • Consulting fees$15,34813%
  • Speaking & faculty fees$72,25760%
  • Grants$420%
  • Travel & lodging$7,5806%
  • Food & beverage$25,64121%
  • Education$2020%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Eisai Inc.157$215,652
Sage Therapeutics, LLC22$145,808
Lilly USA, LLC131$66,074
Idorsia Pharmaceuticals US Inc9$23,433
AbbVie(2 entities)174$5,065
Genentech USA, Inc.22$4,878
Biogen69$3,714
Novartis126$3,214
Supernus Pharmaceuticals, Inc.74$1,532
MDD US Operations, LLC52$1,102
Pfizer55$992
EMD Serono, Inc.53$759
Amgen(2 entities)46$754
UCB, Inc.38$735
Sanofi29$656
AstraZeneca(2 entities)26$502
Lundbeck LLC26$485
Teva Pharmaceuticals USA, Inc.24$470
Kyowa Kirin, Inc.25$405
Acadia Pharmaceuticals Inc20$403
Biohaven Pharmaceutical Holding Company Ltd.30$402
Argenx US, Inc.22$397
Greenwich Biosciences, Inc.14$386
Johnson & Johnson(2 entities)13$345
Amneal Pharmaceuticals LLC19$341
CSL Behring14$338
Alnylam Pharmaceuticals Inc.15$332
Adamas Pharmaceuticals, Inc.16$309
Grifols USA, LLC15$309
Neurocrine Biosciences, Inc.17$303
Biohaven Pharmaceuticals, Inc.15$295
TG Therapeutics, Inc.13$280
Sumitomo Pharma America, Inc.13$279
SK Life Science, Inc.13$256
Banner Life Sciences, LLC10$224
Otsuka America Pharmaceutical, Inc.10$206
Acorda Therapeutics, Inc11$194
Harmony Biosciences LLC9$193
Avanir Pharmaceuticals, Inc.21$185
Takeda Pharmaceuticals U.S.A., Inc.8$185
Neurelis, Inc.10$183
Octapharma USA, Inc.9$182
Catalyst Pharmaceuticals, Inc.7$180
Upsher-smith Laboratories LLC8$153
Currax Pharmaceuticals LLC7$121
Jazz Pharmaceuticals Inc.6$120
Avion Pharmaceuticals7$109
Ipsen Biopharmaceuticals, Inc6$104
ANI Pharmaceuticals, Inc.4$102
Merck5$83
Tanabe Pharma America, Inc.3$78
Assertio Therapeutics, Inc.4$77
Axsome Therapeutics, Inc.2$64
Impel Pharmaceuticals LLC4$60
Aprecia Pharmaceuticals, LLC3$48
Bausch Health US, LLC2$47
Averitas Pharma Inc.2$45
C2n Diagnostics, LLC2$44
Cycle Pharmaceuticals Inc2$44
Bristol Myers Squibb3$43

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$484,725 in reported general payments places this provider in the 95th percentile of 506 neurology providers in Georgia.

See all neurology providers in Georgia

Medicare billing

Part B allowed, 2024
$988,050
Medicare patients
274
Services billed
87,297

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5080$567,795
WakixPitolisant Hcl12$195,524
Gamunex-CImmune Globul G/Gly/Iga Avg 4618$183,117
Kesimpta PenOfatumumab11$94,466
GlatopaGlatiramer Acetate20$46,158
Nurtec OdtRimegepant Sulfate31$41,856
Aimovig AutoinjectorErenumab-Aooe35$29,834
Emgality PenGalcanezumab-Gnlm35$26,524
BotoxOnabotulinumtoxina17$21,706
NamzaricMemantine Hcl/Donepezil Hcl28$18,614
QuliptaAtogepant16$17,273
Topiramate ErTopiramate42$17,125
AptiomEslicarbazepine Acetate11$15,864
Maxalt MltRizatriptan Benzoate17$12,259
Lamictal XrLamotrigine12$11,325

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid$185$567,79580 claims
Harmony Biosciences LLCWakix$193$195,52412 claims
Grifols USA, LLCGamunex-C$309$183,11718 claims
AbbVieBotox, Namzaric, Qulipta$5,065$57,59361 claims
PfizerNurtec Odt$992$41,85631 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide$341$6,36130 claims
Upsher-smith Laboratories LLCTopiramate$153$1,088106 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 506 neurology providers in Georgia.

Other neurology in Atlanta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →